Pea hull fiber
Dietary SupplementSnacks containing 15 g/day of ground pea hulls.
NCT Number: NCT03354364
The purpose of this study is to determine the effects of daily consumption of snacks with and without pea hull fiber on gastrointestinal function, gastrointestinal symptoms, food intake, appetite, changes in fecal and microbial composition and activity. Fifty maintenance hemodialysis hemodialysis and CKD patients in stage 4 or 5 will be recruited to participate in a randomized, blinded, 13-week cross-over study evaluating snack foods containing 15 g/d of pea hull fiber.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Interventional
Not applicable
Food Science and Human Department, Gainesville, Florida, United States
Maintenance hemodialysis hemodialysis and CKD patients in stage 4 or 5 (n=50) will be recruited for the study. A randomized, controlled, double-blind, cross-over study will be carried out. Following a 1-week baseline, participants will be assigned to receive snacks with pea hull fiber or control followed by a 4-week wash-out period, and then crossed over to the second intervention. Snacks with added pea hull fiber (15 g/d) and control will be provided to participants in identical packaging. Participants will collect 4 days of stools during the baseline week, week 5, 9, and 13 and analyzed for mineral content. Microbiota composition will be analyzed including microbial diversity, qPCR to quantify changes and 16S rRNA sequencing to identify pea hull fiber effects on specific bacteria. Following baseline, participants will attend a second visit and anthropometric and demographic information will be collected and we will measure blood pressure, the body composition by bioelectrical impedance analysis (BIA), and handgrip strength using a dynamometer.
Throughout the study, participants must complete a daily questionnaire to evaluate the transit time (eg. Bristol Stool Scale), stool frequency, and compliance. Every week, questionnaires to evaluate appetite (eg. SNAQ) and GI wellness (eg. GSRS - Gastrointestinal Symptom Response Scale) will be administered. During each study visit, participants will complete a questionnaire to evaluate the quality of life. In addition, the dietary data (24-hour diet recalls) will be collected by phone during the baseline week and during the last week of each period. During baseline, treatment and each washout, fasting blood will be collected and analyzed for a comprehensive metabolic panel with eGFR, in addition to microbial metabolites (e.g., indoxyl sulfate and p-cresyl sulfate), and inflammatory markers (e.g. CRP, TNFα, IL-6).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Snacks containing 15 g/day of ground pea hulls.
Snacks without added fiber.
Time frame: baseline, 5 weeks, 9 weeks, 13 weeks
Change in serum levels of microbial metabolic product, p-cresyl sulfate
Time frame: baseline, 5 weeks, 9 weeks, 13 weeks
Change in serum levels microbial metabolic products (e.g. indoxyl sulfate, TMAO, phenylacetyl glutamine etc.)
Time frame: at baseline, week 5, week 9 and week 12.
Change in fecal concentration of microbial metabolites and minerals
Time frame: 13 weeks
Change in number of stools per week and mean number of stools per week per period
Time frame: 13 weeks
Change in stool form determined using Bristol Stool Form Scale
Time frame: at weeks 1 through 13
Change in gastrointestinal symptom score determined by GSRS (Gastrointestinal Symptom Response Scale)
Time frame: baseline, weeks 5, 9 and 13
change at phylum and genus levels; changes in operational taxonomic units (OTUs)
Time frame: baseline, weeks 5, 9 and 13
Change in dietary energy, macronutrient and fiber intake
Time frame: at weeks 1 through 13
Change in appetite determined by SNAQ questionnaire
Time frame: baseline, weeks 5, 9 and 13
Change in Kidney Disease Quality of Life questionnaire (KDQOL®-36)
University of Florida
Other
Efficacy of Pea Hull Fiber Supplementation on Gastrointestinal Transit Time-induced Reduction in Proteolytic Fermentation and Enhancement of Wellness in Individuals With Lifestyle-related Chronic Disease and Overweight. (Phase 3)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06461273
Behavior, Body Weight
Newark, New Jersey, United States
View Trial DetailsNCT06287073
Chronic Disease, Disease Attributes
Anyang, South Korea
View Trial DetailsNCT05490511
CBD, Chronic Disease
Indianapolis, Indiana, United States
View Trial DetailsNCT03816111
Chronic Disease, Disease Attributes
Canberra, Australian Capital Territory, Australia
View Trial Details